Stay updated on SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.

Latest updates to the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to the trial details content or layout were observed, indicating an internal update.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated to v3.4.3; the previous v3.4.2 tag was removed.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing Revision: v3.4.1. No core study details or results appear to be altered.SummaryDifference0.0%

- Check59 days agoChange DetectedA new Revision: v3.4.1 entry was added and the previous Revision: v3.4.0 entry was removed.SummaryDifference0.0%

- Check81 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the site, with no evident changes to the study details, eligibility criteria, locations, or outcomes. This appears to be a non-substantive update focused on the site's versioning. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check102 days agoChange DetectedLocations section now lists participating states (Connecticut, Florida, Iowa, Massachusetts, Michigan, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas). The HHS Vulnerability Disclosure link was removed.SummaryDifference1%

Stay in the know with updates to SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.